geneMAP™ MLH1 Methylation Analysis Kit (MLH1-RT50)
- Superior Analytical Sensitivity and specificity with Methylation Specific PCR
- Fast and Easy to Use with Multiplex Realtime PCR Technology
- Quantitative Methylation Analysis (Calculation of Methylation Level %)
- Compatible with FAM, VIC/HEX two Colors Real-Time PCR Instruments
Lynch syndrome is an autosomal dominant, inherited cancer syndrome due to a germline mutation in a gene controlling DNA mismatch repair (MMR), such as MLH1, MSH2, MSH6 or PMS2. Lynch Syndrome is thought to account for 1-6% of all endometrial cancers. For women with Lynch Syndrome, the lifetime risk of endometrial cancer is 60%, while the lifetime risk of colorectal cancer is 39-54%. Endometrial cancer or ovarian cancer precede the diagnosis of colorectal cancer in approximately half of women with Lynch Syndrome, leading to the concept of these gynecological cancers being a sentinel cancer for these women. Diagnosis of Lynch Syndrome at the time of sentinel cancer diagnosis provides the patient with the opportunity to undergo surveillance for other cancers associated with Lynch Syndrome, especially colorectal cancer. Identification of Lynch Syndrome at the time of sentinel cancer diagnosis also impacts family members, as they can be subsequently tested and appropriate cancer prevention surveillance initiated for affected individuals.